Energy Transfer Equity, L.P. (ETE) saw its value decrease by -1.24% as the stock dropped $-0.24 to finish the day at a closing price of $19.12. The stock was lighter in trading and has fluctuated between $5.94-$20.05 per share for the past year. The shares, which traded within a range of $19.06 to $19.54 during the day, are up by 15.18% in the past three months and up by 11.9% over the past six months. It is currently trading 3.43% above its 20 day moving average and 4.78% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $19.84 a share over the next twelve months. The current relative strength index (RSI) reading is 57.24.The technical indicator lead us to believe there will be no major movement any time soon, hold.
Energy Transfer Equity, L.P. provides diversified energy-related services in the Unites States. It owns and operates approximately 7,500 miles of natural gas transportation pipelines and three natural gas storage facilities in Texas; and approximately 12,300 miles of interstate natural gas pipelines. The company sells natural gas to electric utilities, independent power plants, local distribution companies, industrial end-users, and other marketing companies. Its midstream operations include ownership and operation of approximately 35,000 miles of in service natural gas pipelines, 31 natural gas processing plants, 21 natural gas treating facilities, and 4 natural gas conditioning facilities in Texas, New Mexico, West Virginia, Pennsylvania, and Louisiana; operation of natural gas gathering, oil pipeline, and oil stabilization facilities in South Texas, as well as a natural gas gathering system in Ohio; and transportation and supply of water to natural gas producers in Pennsylvania. The company’s natural gas liquid (NGL) transportation and services operations include ownership of approximately 2,000 miles of NGL pipelines, three NGL processing plants, four NGL and propane fractionation facilities, and NGL storage facilities. It also sells gasoline and middle distillates at retail; operates convenience stores primarily on the east coast and in the Midwest region of the United States; and gathers, purchases, stores, transports, markets, and sells crude oil, NGLs, and refined products. In addition, it provides natural gas compression services; treating services, such as carbon dioxide and hydrogen sulfide removal, natural gas cooling, dehydration, and British thermal unit management services; and manages coal and natural resources properties, as well as sells standing timber, leases coal-related infrastructure facilities, collects oil and gas royalties, and generates a total of 75 megawatts electrical power. The company was founded in 2002 and is based in Dallas, Texas.
American Airlines Group Inc. (AAL) shares were down in last trading by -1.2% to $46.97. It experienced lighter than average volume on day. The stock increased in value by almost 1.45% over the past week and fell -1.19% in the past month. It is currently trading -0.17% below its 50 day moving average and 21.57% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -7.04% decrease in value from its one year high of $50.64. The RSI indicator value of 52.59, lead us to believe that it is a hold for now.
American Airlines Group Inc., through its subsidiaries, operates in the airline industry. As of December 31, 2015, the company operated a mainline fleet of 946 aircraft. It serves 350 destinations in approximately 50 countries. The company was formerly known as AMR Corporation and changed its name to American Airlines Group Inc. in December 2013. American Airlines Group Inc. was founded in 1934 and is headquartered in Fort Worth, Texas.
AbbVie Inc. (ABBV) traded within a range of $60.81 to $61.91 after opening the day at $61.67. The company has seen its stock decrease in value by -0.83% so far this year. The stock was down close to -0.28% on light volume in last trading session and closed at $61.48 per share. After the recent fall, the stock is currently holding -8% below its 52 week high of $68.12 and 21.05% above its 12-month low of $53.74. The shares are down by over -1.22% in the last three months, and the RSI indicator value of 54.64 is neither bullish nor bearish, tempting investors to stay on the sidelines.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.